Angiotensin II: A Review of Current Literature
Up to one-third of all patients admitted to intensive care units carry a diagnosis of shock. The use of angiotensin II is becoming widespread in all forms of shock, including cardiogenic, after the Food and Drug Administration initial approval for vasoplegic shock in 2017. We review the literature on angiotensin II's mechanism of action, benefits, and future therapeutic opportunities.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Amit Alam, William Sovic, Jasmeet Gill, Nikolaus Ragula, Mahmoud Salem, GregoryJ. Hughes, Gates B. Colbert, Jennifer L. Mooney Source Type: research
More News: Anesthesia | Anesthesiology | Cardiology | Food and Drug Administration (FDA) | Heart | Intensive Care